Gert Fricker

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9045826/publications.pdf

Version: 2024-02-01

171	8,670	36303	53230
papers	citations	51 h-index	85 g-index

181	181	181	9700
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Zebrafish (Danio rerio) larva as an in vivo vertebrate model to study renal function. American Journal of Physiology - Renal Physiology, 2022, 322, F280-F294.	2.7	14
2	Synthesis and Characterization of Biodegradable Poly(butyl cyanoacrylate) for Drug Delivery Applications. Polymers, 2022, 14, 998.	4.5	3
3	Targeting Transporters for Drug Delivery to the Brain: Can We Do Better?. Pharmaceutical Research, 2022, 39, 1415-1455.	3.5	24
4	Re-evaluation of the hCMEC/D3 based in vitro BBB model for ABC transporter studies. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 173, 12-21.	4.3	9
5	Altered protein expression of membrane transporters in isolated cerebral microvessels and brain cortex of a rat Alzheimer's disease model. Neurobiology of Disease, 2022, 169, 105741.	4.4	14
6	Extension of the Mechanistic Tissue Distribution Model of Rodgers and Rowland by Systematic Incorporation of Lysosomal Trapping: Impact on Unbound Partition Coefficient and Volume of Distribution Predictions in the Rat. Drug Metabolism and Disposition, 2021, 49, 53-61.	3.3	10
7	Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFAlin-Modified Peptidic Radioligands Targeting Both Integrin Î±vÎ²3 and the MC1 Receptorâ€"Suitable for the Specific Visualization of Melanomas?. Pharmaceuticals, 2021, 14, 547.	3.8	7
8	Crossing the blood-brain barrier: A review on drug delivery strategies using colloidal carrier systems. Neurochemistry International, 2021, 147, 105017.	3.8	17
9	Trends in liposomal nanocarrier strategies for the oral delivery of biologics. Nanomedicine, 2021, 16, 1813-1832.	3.3	7
10	Potential and Limits of Kidney Cells for Evaluation of Renal Excretion. Pharmaceuticals, 2021, 14, 908.	3.8	6
11	Blood-brain barrier models: Rationale for selection. Advanced Drug Delivery Reviews, 2021, 176, 113859.	13.7	23
12	Overcoming the Mucosal Barrier: Tetraether Lipidâ€Stabilized Liposomal Nanocarriers Decorated with Cellâ€Penetrating Peptides Enable Oral Delivery of Vancomycin. Advanced Therapeutics, 2021, 4, 2000247.	3.2	16
13	Side-by-Side Comparison of Five Chelators for 89Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability. Cancers, 2021, 13, 6349.	3.7	12
14	David S. Miller: Scientist, Mentor, Friendâ€"a tribute and thank you. Fluids and Barriers of the CNS, 2020, 17, 56.	5.0	0
15	Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy. Pharmaceuticals, 2020, 13, 173.	3.8	16
16	The influence of liquid intake on the performance of an amorphous solid dispersion in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 296-298.	4.3	3
17	Physicochemical and biopharmaceutical characterization of novel Matrix-Liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 153, 158-167.	4.3	2
18	Sugar Codes Conjugated Alginate: An Innovative Platform to Make a Strategic Breakthrough in Simultaneous Prophylaxis of GERD and Helicobacter pylori Infection . Drug Design, Development and Therapy, 2020, Volume 14, 2405-2412.	4.3	1

#	Article	IF	Citations
19	Lipid Profiles of Five Essential Phospholipid Preparations for the Treatment of Nonalcoholic Fatty Liver Disease: A Comparative Study. Lipids, 2020, 55, 271-278.	1.7	9
20	Dual asymmetric centrifugation as a novel method to prepare highly concentrated dispersions of PEG-b-PCL polymersomes as drug carriers. International Journal of Pharmaceutics, 2020, 579, 119087.	5.2	10
21	Drug Delivery Strategies to Overcome the Bloodâ€“Brain Barrier (BBB). Handbook of Experimental Pharmacology, 2020, , 151-183.	1.8	8
22	The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl-Lysophosphatidylethanolamide (UDCA-LPE) Disintegrates the Lipid Backbone of Raft Plasma Membrane Domains by the Removal of the Membrane Phospholipase A2. International Journal of Molecular Sciences, 2019, 20, 5631.	4.1	1
23	Aryl hydrocarbon receptor ligands increase ABC transporter activity and protein expression in killifish (Fundulus heteroclitus) renal proximal tubules. Biological Chemistry, 2019, 400, 1335-1345.	2.5	11
24	Quantitation of Lysosomal Trapping of Basic Lipophilic Compounds Using In Vitro Assays and In Silico Predictions Based on the Determination of the Full pH Profile of the Endo-/Lysosomal System in Rat Hepatocytes. Drug Metabolism and Disposition, 2019, 47, 49-57.	3.3	33
25	Impact of Zn²⁺ on ABC Transporter Function in Intact Isolated Rat Brain Microvessels, Human Brain Capillary Endothelial Cells, and in Rat in Vivo. Molecular Pharmaceutics, 2019, 16, 305-317.	4.6	9
26	Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging. Pharmaceuticals, 2019, 12, 7.	3.8	9
27	Identification of [¹⁸F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging. Journal of Medicinal Chemistry, 2018, 61, 1737-1743.	6.4	36
28	Synthesis, in vitro and in vivo evaluation of 18 F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors. Nuclear Medicine and Biology, 2018, 57, 1-11.	0.6	3
29	Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y1)- and GRP-Receptorsâ€”An Improvement for Breast Cancer Imaging?. Pharmaceuticals, 2018, 11, 65.	3.8	11
30	Archaeal lipids in oral delivery of therapeutic peptides. European Journal of Pharmaceutical Sciences, 2017, 108, 101-110.	4.0	35
31	Development and characterization of novel highly-loaded itraconazole poly(butyl cyanoacrylate) polymeric nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 175-185.	4.3	28
32	Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2771-2775.	2.2	10
33	Zinc chloride rapidly stimulates efflux transporters in renal proximal tubules of killifish (Fundulus) Tj ETQq1 1 0.784314 rgBT /Overloc	2.8	10
34	Oral delivery of vancomycin by tetraether lipid liposomes. European Journal of Pharmaceutical Sciences, 2017, 108, 111-118.	4.0	69
35	InÂVitro and In Situ Characterization of Triterpene Glycosides From Cimicifuga racemosa Extract. Journal of Pharmaceutical Sciences, 2017, 106, 3642-3650.	3.3	5
36	A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human. Journal of Medicinal Chemistry, 2017, 60, 6897-6910.	6.4	20

#	Article	IF	Citations
37	Electrospray Synthesis of Poly(lactide-co-glycolide) Nanoparticles Encapsulating Peptides to Enhance Proliferation of Antigen-Specific CD8+ T Cells. Journal of Pharmaceutical Sciences, 2017, 106, 3316-3327.	3.3	18
38	The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers â€" An in vitro and in vivo comparison. European Journal of Pharmaceutical Sciences, 2017, 108, 13-22.	4.0	18
39	Blood Trimethylamine-N-Oxide Originates from Microbiota Mediated Breakdown of Phosphatidylcholine and Absorption from Small Intestine. PLoS ONE, 2017, 12, e0170742.	2.5	40
40	Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimerâ€™s disease treatment. Colloids and Surfaces B: Biointerfaces, 2016, 145, 8-13.	5.0	140
41	Delivery of Copper-chelating Trientine (TETA) to the central nervous system by surface modified liposomes. International Journal of Pharmaceutics, 2016, 512, 87-95.	5.2	33
42	ABC transporters at the bloodâ€“brain barrier. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 499-508.	3.3	121
43	Comparative Assessment of Complex Stabilities of Radiocopper Chelating Agents by a Combination of Complex Challenge and in vivo Experiments. ChemMedChem, 2015, 10, 1200-1208.	3.2	18
44	Liposomal Conjugates for Drug Delivery to the Central Nervous System. Pharmaceutics, 2015, 7, 27-42.	4.5	39
45	Development and lyophilization of itraconazole loaded poly(butylcyanoacrylate) nanospheres as a drug delivery system. European Journal of Pharmaceutical Sciences, 2015, 78, 121-131.	4.0	15
46	Dual ligand immunoliposomes for drug delivery to the brain. Colloids and Surfaces B: Biointerfaces, 2015, 134, 213-219.	5.0	52
47	Characterization of efflux transport proteins of the human choroid plexus papilloma cell line HIBCPP, a functional in vitro model of the blood-cerebrospinal fluid barrier. Pharmaceutical Research, 2015, 32, 2973-2982.	3.5	26
48	Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases. Pharmaceutical Research, 2015, 32, 2060-2071.	3.5	27
49	Nanotoxicity of poly(n-butylcyano-acrylate) nanoparticles at the bloodâ€“brain barrier, in human whole blood and in vivo. Journal of Controlled Release, 2015, 197, 165-179.	9.9	58
50	Radionuclides in drug development. Drug Discovery Today, 2015, 20, 198-208.	6.4	29
51	Current Status in the Therapy of Liver Diseases. International Journal of Molecular Sciences, 2014, 15, 7500-7512.	4.1	34
52	Improved Oral Bioavailability of Human Growth Hormone by a Combination of Liposomes Containing Bio-Enhancers and Tetraether Lipids and Omeprazole. Journal of Pharmaceutical Sciences, 2014, 103, 3985-3993.	3.3	61
53	Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1. Phytomedicine, 2014, 21, 323-332.	5.3	33
54	Establishment of Optimized MDCK Cell Lines for Reliable Efflux Transport Studies. Journal of Pharmaceutical Sciences, 2014, 103, 1298-1304.	3.3	44

#	Article	IF	Citations
55	What Is the Mechanism Behind Increased Permeation Rate of a Poorly Soluble Drug from Aqueous Dispersions of an Amorphous Solid Dispersion?. Journal of Pharmaceutical Sciences, 2014, 103, 1779-1786.	3.3	91
56	Matrix liposomes: A solid liposomal formulation for oral administration. European Journal of Lipid Science and Technology, 2014, 116, 1145-1154.	1.5	25
57	Shuttleâ€“Cargo Fusion Molecules of Transport Peptides and the hD_{2/3}Receptor Antagonist Fallypride: A Feasible Approach To Preserve Ligandâ€“Receptor Binding?. Journal of Medicinal Chemistry, 2014, 57, 4368-4381.	6.4	7
58	Cytotoxicity and inhibition of P-glycoprotein by selected medicinal plants from Thailand. Journal of Ethnopharmacology, 2014, 155, 633-641.	4.1	25
59	In vitro and in vivo evaluations of the performance of an indirubin derivative, formulated in four different self-emulsifying drug delivery systems. Journal of Pharmacy and Pharmacology, 2014, 66, 1567-1575.	2.4	20
60	Development and validation of a LCâ€“MS/MS method for assessment of an anti-inflammatory indolinone derivative by in vitro bloodâ€“brain barrier models. Journal of Pharmaceutical and Biomedical Analysis, 2014, 98, 235-246.	2.8	9
61	Enhancement of Oral Bioavailability of E804 by Self-Nanoemulsifying Drug Delivery System (SNEDDS) in Rats. Journal of Pharmaceutical Sciences, 2013, 102, 3792-3799.	3.3	47
62	Physicochemical characterization and in vitro permeation of an indirubin derivative. European Journal of Pharmaceutical Sciences, 2013, 50, 467-475.	4.0	12
63	In vitro metabolism, permeation, and brain availability of six major boswellic acids from Boswellia serrata gum resins. FÃ¬toterapÃ¬Ã¢, 2013, 84, 99-106.	2.2	60
64	Enhanced absorption of boswellic acids by a lecithin delivery form (PhytosomeÂ®) of Boswellia extract. FÃ¬toterapÃ¬Ã¢, 2013, 84, 89-98.	2.2	101
65	NOD-scid IL2R Î³null mice engrafted with human peripheral blood mononuclear cells as a model to test therapeutics targeting human signaling pathways. Journal of Translational Medicine, 2013, 11, 4.	4.4	10
66	Formulation optimization of itraconazole loaded PEGylated liposomes for parenteral administration by using design of experiments. International Journal of Pharmaceutics, 2013, 448, 189-197.	5.2	34
67	Biopharmaceutical classification of poorly soluble drugs with respect to â€œenabling formulationsâ€. European Journal of Pharmaceutical Sciences, 2013, 50, 8-16.	4.0	158
68	A simple method to quickly and simultaneously purify and enrich intact rat brain microcapillaries and endothelial and glial cells for ex vivo studies and cell culture. Brain Research, 2013, 1519, 9-18.	2.2	1
69	Dynamic Regulation of P-glycoprotein in Human Brain Capillaries. Molecular Pharmaceutics, 2013, 10, 3333-3341.	4.6	38
70	The Bloodâ€“Brain Barrier: An Introduction to Its Structure and Function. Topics in Medicinal Chemistry, 2013, , 1-20.	0.8	4
71	Alkamides from Echinacea angustifolia Interact with P-Glycoprotein of Primary Brain Capillary Endothelial Cells Isolated from Porcine Brain Blood Vessels. Planta Medica, 2013, 79, 214-218.	1.3	7
72	Development of a New Method to Assess Nanocrystal Dissolution Based on Light Scattering. Pharmaceutical Research, 2012, 29, 2887-2901.	3.5	45

#	Article	IF	Citations
73	Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: True supersaturation vs. apparent solubility enhancement. International Journal of Pharmaceutics, 2012, 437, 288-293.	5.2	129
74	Exploring the fate of liposomes in the intestine by dynamic in vitro lipolysis. International Journal of Pharmaceutics, 2012, 437, 253-263.	5.2	30
75	Brain delivery of camptothecin by means of solid lipid nanoparticles: Formulation design, in vitro and in vivo studies. International Journal of Pharmaceutics, 2012, 439, 49-62.	5.2	104
76	Effect of Phospholipid-Based Formulations of Boswellia serrata Extract on the Solubility, Permeability, and Absorption of the Individual Boswellic Acid Constituents Present. Journal of Natural Products, 2012, 75, 1675-1682.	3.0	30
77	Oral bioavailability of ketoprofen in suspension and solution formulations in rats: the influence of poloxamer 188. Journal of Pharmacy and Pharmacology, 2012, 64, 1631-1637.	2.4	13
78	Localization Microscopy (SPDM) Reveals Clustered Formations of P-Glycoprotein in a Human Blood-Brain Barrier Model. PLoS ONE, 2012, 7, e44776.	2.5	26
79	The amorphous solid dispersion of the poorly soluble ABT-102 forms nano/microparticulate structures in aqueous medium: impact on solubility. International Journal of Nanomedicine, 2012, 7, 5757.	6.7	37
80	Inhibition of P-glycoprotein by two artemisinin derivatives. Natural Products and Bioprospecting, 2012, 2, 59-64.	4.3	10
81	Application of simulated intestinal fluid on the phospholipid vesicle-based drug permeation assay. International Journal of Pharmaceutics, 2012, 422, 52-58.	5.2	14
82	In vitro models to evaluate the permeability of poorly soluble drug entities: Challenges and perspectives. European Journal of Pharmaceutical Sciences, 2012, 45, 235-250.	4.0	113
83	Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound. European Journal of Pharmaceutical Sciences, 2012, 47, 16-20.	4.0	61
84	Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, 416-422.	4.3	67
85	In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: the influence of nonionic surfactants. Journal of Pharmacy and Pharmacology, 2011, 63, 1022-1030.	2.4	56
86	The ABC of the Blood-Brain Barrier - Regulation of Drug Efflux Pumps. Current Pharmaceutical Design, 2011, 17, 2762-2770.	1.9	72
87	Engaging neuroscience to advance translational research in brain barrier biology. Nature Reviews Neuroscience, 2011, 12, 169-182.	10.2	508
88	Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties. Journal of Cellular and Molecular Medicine, 2011, 15, 1122-1135.	3.6	49
89	Stability of liposomes containing bio-enhancers and tetraether lipids in simulated gastro-intestinal fluids. International Journal of Pharmaceutics, 2011, 405, 210-217.	5.2	67
90	Oral peptide delivery by tetraether lipid liposomes. International Journal of Pharmaceutics, 2011, 415, 150-157.	5.2	60

#	Article	IF	Citations
91	Biological effects of acrylamide after daily ingestion of various foods in comparison to water: A study in rats. Molecular Nutrition and Food Research, 2011, 55, 387-399.	3.3	26
92	St. Johnâ€™s Wort Constituents Modulate P-glycoprotein Transport Activity at the Blood-Brain Barrier. Pharmaceutical Research, 2010, 27, 811-822.	3.5	39
93	Phospholipids and Lipid-Based Formulations in Oral Drug Delivery. Pharmaceutical Research, 2010, 27, 1469-1486.	3.5	289
94	Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media. European Journal of Pharmaceutical Sciences, 2010, 40, 25-32.	4.0	96
95	Regional absorption of fexofenadine in rat intestine. European Journal of Pharmaceutical Sciences, 2010, 41, 670-674.	4.0	23
96	In situ formation of nanoparticles upon dispersion of melt extrudate formulations in aqueous medium assessed by asymmetrical flow field-flow fractionation. Journal of Pharmaceutical and Biomedical Analysis, 2010, 53, 359-365.	2.8	67
97	Fluoâ€cAMP is transported by multidrug resistanceâ€associated protein isoform 4 in rat choroid plexus. Journal of Neurochemistry, 2010, 115, 200-208.	3.9	13
98	Characterization of immortalized choroid plexus epithelial cell lines for studies of transport processes across the blood-cerebrospinal fluid barrier. Cerebrospinal Fluid Research, 2010, 7, 11.	0.5	25
99	BCRP at the Bloodâ^'Brain Barrier: Genomic Regulation by 17Î²-Estradiol. Molecular Pharmaceutics, 2010, 7, 1835-1847.	4.6	43
100	Development of a fluorescence-based assay for drug interactions with human Multidrug Resistance Related Protein (MRP2; ABCC2) in MDCKII-MRP2 membrane vesicles. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75, 284-290.	4.3	21
101	Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 1-9.	4.3	124
102	In vitro evaluation of liposomes containing bio-enhancers for the oral delivery of macromolecules. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 394-403.	4.3	35
103	Glutaric aciduria type I and methylmalonic aciduria: Simulation of cerebral import and export of accumulating neurotoxic dicarboxylic acids in in vitro models of the bloodâ€“brain barrier and the choroid plexus. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 552-560.	3.8	64
104	In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier. Journal of Pharmacy and Pharmacology, 2010, 62, 1591-1598.	2.4	42
105	Pregnane X Receptor (PXR) Regulates P-Glycoprotein at the Blood-Brain Barrier: Functional Similarities between Pig and Human PXR. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 141-149.	2.5	80
106	Permeation of Boswellia extract in the Caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1B3 and MRP2. European Journal of Pharmaceutical Sciences, 2009, 36, 275-284.	4.0	55
107	Modification with Organometallic Compounds Improves Crossing of the Bloodâ€“Brain Barrier of [Leu⁵]â€Enkephalin Derivatives in an In Vitro Model System. ChemBioChem, 2009, 10, 1852-1860.	2.6	34
108	A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2). European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 605-613.	4.3	22

#	Article	IF	Citations
109	Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) Derived from the p-Glycoprotein (ABCB1) Modulator Tariquidar. Journal of Medicinal Chemistry, 2009, 52, 1190-1197.	6.4	135
110	Uptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries. Journal of Drug Targeting, 2009, 17, 610-618.	4.4	41
111	Compound profiling for ABCC2 (MRP2) using a fluorescent microplate assay system. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 396-403.	4.3	32
112	Delivery of nanoparticles to the brain detected by fluorescence microscopy. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 627-632.	4.3	77
113	Characterization of Cytochrome P450 Protein Expression along the Entire Length of the Intestine of Male and Female Rats. Drug Metabolism and Disposition, 2008, 36, 1039-1045.	3.3	60
114	Closing the Gaps: A Full Scan of the Intestinal Expression of P-Glycoprotein, Breast Cancer Resistance Protein, and Multidrug Resistance-Associated Protein 2 in Male and Female Rats. Drug Metabolism and Disposition, 2008, 36, 1249-1254.	3.3	137
115	Texas Red transport across rat and dogfish shark (Squalus acanthias) choroid plexus. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 295, R1311-R1319.	1.8	11
116	Drug Interactions with Natural Products at the Blood Brain Barrier. Current Drug Metabolism, 2008, 9, 1019-1026.	1.2	14
117	In Vitro Models to Study Blood-Brain Barrier Function. , 2008, , 397-417.		2
118	In vitro Cytotoxicity and P-Glycoprotein Modulating Effects of Geranylated Furocoumarins from Tetradium daniellii. Planta Medica, 2007, 73, 1475-1478.	1.3	21
119	Cytotoxicity and P-Glycoprotein Modulating Effects of Quinolones and Indoloquinazolines from the Chinese Herb Evodia rutaecarpa. Planta Medica, 2007, 73, 1554-1557.	1.3	53
120	Surveillance of siRNA integrity by FRET imaging. Nucleic Acids Research, 2007, 35, e124.	14.5	54
121	Transport of a fluorescent cAMP analog in teleost proximal tubules. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R2382-R2389.	1.8	27
122	Choroid plexus epithelial monolayers--a cell culture model from porcine brain. Cerebrospinal Fluid Research, 2006, 3, 13.	0.5	50
123	Rapid Modulation of P-Glycoprotein-Mediated Transport at the Blood-Brain Barrier by Tumor Necrosis Factor-Î± and Lipopolysaccharide. Molecular Pharmacology, 2006, 69, 462-470.	2.3	185
124	Retention of structural and functional polarity in cultured skate hepatocytes undergoing in vitro morphogenesis. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2006, 144, 167-179.	1.6	10
125	Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency. Journal of Neurochemistry, 2006, 97, 899-910.	3.9	147
126	Rapid assessment of p-glycoproteinâ€“drug interactions at the bloodâ€“brain barrier. Analytical Biochemistry, 2006, 358, 51-58.	2.4	16

#	Article	IF	Citations
127	Fluorescein-methotrexate transport in dogfish shark (Squalus acanthias) choroid plexus. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R464-R472.	1.8	13
128	Modulation of p-Glycoprotein Transport Function at the Blood-Brain Barrier. Experimental Biology and Medicine, 2005, 230, 118-127.	2.4	130
129	Overcoming MDR at the bloodâ€“brain barrier. International Congress Series, 2005, 1277, 131-143.	0.2	4
130	Drug Delivery Across the Blood-Brain Barrier. Current Nanoscience, 2005, 1, 203-209.	1.2	3
131	Fluorescein-methotrexate transport in rat choroid plexus analyzed using confocal microscopy. American Journal of Physiology - Renal Physiology, 2004, 287, F562-F569.	2.7	26
132	Rapid Regulation of P-Glycoprotein at the Blood-Brain Barrier by Endothelin-1. Molecular Pharmacology, 2004, 66, 387-394.	2.3	152
133	Lack of biliary lipid excretion in the little skate, Raja erinacea, indicates the absence of functional Mdr2, Abcg5, and Abcg8 transporters. American Journal of Physiology - Renal Physiology, 2004, 286, G762-G768.	3.4	12
134	Modulation of Drug Transporters at the Blood-Brain Barrier. Pharmacology, 2004, 70, 169-176.	2.2	93
135	Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system. Pharmaceutical Research, 2003, 20, 1170-1176.	3.5	45
136	Modulation of transendothelial permeability and expression of ATP-binding cassette transporters in cultured brain capillary endothelial cells by astrocytic factors and cell-culture conditions. Experimental Brain Research, 2003, 153, 356-365.	1.5	38
137	Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. British Journal of Pharmacology, 2003, 140, 1201-1210.	5.4	86
138	By-passing of P-glycoprotein Using Immunoliposomes. Journal of Drug Targeting, 2002, 10, 73-79.	4.4	120
139	Short- and Long-Term Influences of Heavy Metals on Anionic Drug Efflux from Renal Proximal Tubule. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 578-585.	2.5	45
140	Cloning and Characterization of a Novel Apolipoprotein A-I Binding Protein, AI-BP, Secreted by Cells of the Kidney Proximal Tubules in Response to HDL or ApoA-I. Genomics, 2002, 79, 693-702.	2.9	69
141	Xenobiotic efflux pumps in isolated fish brain capillaries. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2002, 282, R191-R198.	1.8	69
142	Confocal imaging of organic anion transport in intact rat choroid plexus. American Journal of Physiology - Renal Physiology, 2002, 282, F877-F885.	2.7	32
143	Relevance of Multidrug Resistance Proteins for Intestinal Drug Absorptionin vitroandin vivo. Basic and Clinical Pharmacology and Toxicology, 2002, 90, 5-13.	0.0	58
144	Permeability of porcine blood brain barrier to somatostatin analogues. British Journal of Pharmacology, 2002, 135, 1308-1314.	5.4	45

#	Article	IF	Citations
145	Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. Journal of Clinical Investigation, 2002, 110, 1309-1318.	8.2	280
146	Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. Journal of Clinical Investigation, 2002, 110, 1309-1318.	8.2	159
147	Drug transport across the bloodâ€šÃ„Ã¬brain barrier â€šÃ„Ã¬ a molecular and functional perspective. , 2002, , 327-336.		0
148	Ivermectin excretion by isolated functionally intact brain endothelial capillaries. British Journal of Pharmacology, 2001, 132, 722-728.	5.4	42
149	Xenobiotic Transport across Isolated Brain Microvessels Studied by Confocal Microscopy. Molecular Pharmacology, 2000, 58, 1357-1367.	2.3	291
150	Vergleichende Untersuchungen zur TeilchengrÃ¶ÃŸenanalyse. Chemie-Ingenieur-Technik, 2000, 72, 273-276.	0.8	2
151	P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. British Journal of Pharmacology, 2000, 129, 251-256.	5.4	35
152	Improvement of intestinal peptide absorption by a synthetic bile acid derivative, cholylsarcosine. European Journal of Pharmaceutical Sciences, 2000, 10, 133-140.	4.0	48
153	Endocytosis and Transcytosis of an Immunoliposome-Based Brain Drug Delivery System. Journal of Drug Targeting, 2000, 8, 435-446.	4.4	101
154	Interactions of HIV Protease Inhibitors with ATP-Dependent Drug Export Proteins. Molecular Pharmacology, 1999, 56, 383-389.	2.3	178
155	Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharmaceutical Research, 1999, 16, 402-407.	3.5	105
156	Epithelial transport of anthelmintic ivermectin in a novel model of isolated proximal kidney tubules. Pharmaceutical Research, 1999, 16, 1570-1575.	3.5	36
157	Sister of P-glycoprotein expression in different tissues. Biochemical Pharmacology, 1999, 57, 833-835.	4.4	39
158	HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochemical Pharmacology, 1999, 57, 1147-1152.	4.4	176
159	Enterohepatic circulation of scymnol sulfate in an elasmobranch, the little skate (<i>Raja) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	3.4	14
160	Evidence for Pâ€glycoproteinâ€modulated penetration of morphineâ€6â€glucuronide into brain capillary endothelium. British Journal of Pharmacology, 1996, 118, 1879-1885.	5.4	108
161	Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-Methyl-D-aspartate receptor antagonistsâ€"II. Pharmacological characterization in vivo. Neuropharmacology, 1996, 35, 655-669.	4.1	21
162	Cyclodextrins â€" Useful excipients for oral peptide administration?. International Journal of Pharmaceutics, 1996, 137, 103-110.	5.2	50

#	Article	IF	Citations
163	Nasal delivery of octreotide: Absorption enhancement by particulate carrier systems. International Journal of Pharmaceutics, 1996, 139, 25-32.	5.2	35
164	Current Concepts in Intestinal Peptide Absorption. Journal of Peptide Science, 1996, 2, 195-211.	1.4	41
165	Intestinal Absorption of Sugar-coupled Somatostatin Analogs. Journal of Pharmaceutical Sciences, 1996, 85, 1211-1214.	3.3	1
166	Quantification and visualization of the transport of octreotide, a somatostatin analogue, across monolayers of cerebrovascular endothelial cells. Pharmaceutical Research, 1994, 11, 442-448.	3.5	33
167	HIV proteinase inhibitors containing 2-aminobenzylstatine as a novel scissile bond replacement: biochemical and pharmacological characterization. Antiviral Research, 1994, 25, 215-233.	4.1	11
168	SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activity. Life Sciences, 1993, 53, 517-525.	4.3	66
169	Enteral absorption of octreotide: absorption enhancement by polyoxyethyleneâ€24â€cholesterol ether. British Journal of Pharmacology, 1993, 108, 298-303.	5.4	51
170	Intestinal absorption of the octapeptide SMS 201â€“995 visualized by fluorescence derivatization. Gastroenterology, 1991, 100, 1544-1552.	1.3	43
171	Identification of Different Transport Systems for Bile Salts in Sinusoidal and Canalicular Membranes of Hepatocytes. Biological Chemistry Hoppe-Seyler, 1987, 368, 1143-1150.	1.4	31